和鉑醫藥-B(02142.HK)與百圖生科達成戰略合作 啟動人工智能新藥研發戰略
格隆匯5月12日丨和鉑醫藥今日宣佈與百圖生科達成戰略合作協議,雙方將在科學研究、新技術產業落地、新產品開發和轉化等領域,進行全方位的戰略合作,開拓計算技術與研發平台的融合,開創人工智能新藥研發的新紀元。
據悉,百圖生科由百度創始人李彥宏發起創立並擔任董事長,是中國首家生物計算引擎驅動的生命科學公司。此次合作將以和鉑醫藥的全人源轉基因小鼠平台為基點,結合百圖生科在人工智能領域的優勢,針對製藥業公認的具有挑戰性的靶點進行共同開發。
通過此次合作,人工智能技術將與和鉑醫藥強大的平台技術相結合,革新和賦能新藥研發、生產與申報全流程等方面,全面推進研發協同與技術創新的深度融合,並針對相關潛在治療靶點開發新藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.